IL17A and COVID-19: Specifically, tocilizumab, an anti-IL-6 receptor monoclonal antibody, has been found to be effective in regulating the levels of cytokines such as IL-6 and IL-17 and its administration in COVID-19 patients has been shown to reduce the lethality rate at 30 days (15, 21).